Common causes for ICU admission include opportunistic infections, complications of ART, and/or medicalsurgical issues not directly related to HIV infection. 3 HIV-related opportunistic infections that may lead to admission to the ICU include Pneumocystis pneumonia, toxoplasmosis-associated encephalitis, cryptococcal meningitis, and bacterial pneumonia. [4] [5] [6] Complications related to prolonged ART include cardiac conditions such as accelerated atherosclerosis, lipid disorders, and hypertension 4, 5 ; metabolic abnormalities such as pancreatitis, insulin resistance, diabetes, and lactic acidosis 4, 7 ; and immune reconstitution inflammatory syndrome (IRIS), an inflammatory response characterized by an increase in CD4 + T-cell count and a decrease in viral load that is triggered after the initiation of ART. [3] [4] [5] [6] [7] [8] [9] In addition, patients with HIV/ AIDS can be admitted to an ICU because of trauma, elective surgery, gastrointestinal bleeding, and chronic heart and lung conditions unrelated to the diagnosis of HIV/AIDS. 4, 5 Critical care nurses who provide care for persons with HIV/AIDS face many complexities related to the administration of ART. Potential interactions between antiretroviral drugs and commonly administered ICU medications, including antiarrhythmics, benzodiazepines, H 2 antagonists, proton pump inhibitors, and anticoagulants, must be considered in planning nursing care. 7 Critical care nurses must be prepared to advocate for HIV-infected persons by initiating or participating in conversations with the health care team about whether to begin, continue, or discontinue ART in the context of each patient's medical and pharmacological situation.
Antiretroviral Therapy
ART, especially highly active antiretroviral therapy introduced in 1996, has revolutionized care of persons with HIV/AIDS by dramatically increasing the person's lifespan and quality of life. 2, 3 The most effective reduction in viral load and restoration of immune function require a combination of antiretroviral drugs. Currently, more than 20 antiretroviral drugs divided into 6 drug classes according to the mechanism of action are used in ART: nucleoside/ nucleotide reverse transcriptase inhibitors (NRTIs), nonnucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), fusion inhibitors, chemokine receptor 5 antagonists, and integrase strand transfer inhibitors. 8 In March 2012, the US Department of Health and Human Services issued guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 8 Four ART regimens are preferred for persons who have never received ART (treatment-naive). The regimens include a combination of 2 NRTIs with a NNRTI, a boosted PI, or an integrase strand transfer inhibitor. 8 These regimens have demonstrated efficacy and are currently recommended for treatment of HIV infection because of their virological activity, tolerability, low toxicity level, and ease of use. 8 Alternative regimens may be established for persons who are not candidates for these preferred regimens because of drug resistance, comorbid conditions, pregnancy, genetics, or other individual characteristics. For example, tenofovir, a common agent used in first-line therapy, may not be clinically indicated for patients with renal insufficiency or acute renal failure. 3 Whether a patient is treatment naive or treatment experienced, selection of an appropriate ART regimen should involve genotypic drug-resistance testing of the virus, evaluation of potential adverse effects and drug interactions, convenience (ie, number of pills that must be taken and dosage frequency), and the patient's comorbid conditions. 8 Adherence is vital to the efficacy of an ART regimen. If ART is to be started in the ICU, critical care nurses must be prepared to educate patients about the importance of adherence. Failure to adhere strictly to an ART regimen may result in drug resistance due to viral mutation. If the virus becomes drug resistant, that regimen, and potentially an entire class of antiretroviral drugs, may become permanently ineffective. 7 Failure to adhere to or discontinuation of an ART regimen may also result in a rapid decrease in CD4 + T-cell count and an increased risk for HIV transmission.
ART in the ICU

ART and Drug Interactions
Critical care nurses must be aware of the frequency and seriousness of ART-drug interactions in order to coordinate and implement care. Consider the following scenario:
A 55-year-old woman is admitted to the ICU after a motor vehicle crash. HIV infection was diagnosed 2 years earlier. The woman has been adherent to ART, and her CD4 + T-cell counts have increased from baseline and her viral load is undetectable. She is currently on a preferred regimen for treatment-naive patients, which includes ritonavirboosted atazanavir (a boosted PI) and tenofovir/ emtricitabine (NRTIs). Like many patients admitted to the ICU, she has been taking pantoprazole (Protonix) as part of an ulcer-prevention protocol. The patient was also prescribed midazolam (Versed) as needed for anxiety. However, when the midazolam was administered in the ICU, she experienced marked respiratory depression and required intubation.
Providing care for any critically ill patient, including persons with HIV/AIDS, requires collaboration between critical care nurses and other members of the health care team to reconcile medications, including prescription and over-the-counter medications and complementary and alternative supplements. Critical care nurses' leadership in medication reconciliation to reduce the risk for drug-drug interactions and possible adverse events can promote patients' safety and quality outcomes. 10 Antiretrovirals interact with many drugs, including other antiretrovirals, medications used to treat and prevent opportunistic infections, and numerous drugs often administered in the ICU. 4 Drug classes that interact with antiretrovirals include acid reducers (both H 2 antagonists and proton-pump inhibitors), antiarrhythmics, anticoagulants, anticonvulsants, anti-infectives, benzodiazepines, calcium channel blockers, corticosteroids, hormonal contraceptives, inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase), and phosphodiesterase inhibitors. The 2 most common classes of ART drugs that interact with other pharmacological agents are PIs and NNRTIs.
8 Table 1 provides an overview of interactions between antiretrovirals and other drugs and clinical considerations related to the interactions. Antiretroviral-drug interactions can cause elevation of serum drug levels, potentially increasing risk for toxic effects. Many antiretroviral drugs inhibit the hepatic cyto chrome P450 system, slowing the metabolism of other drugs. For example, for patients who take digoxin, administration of ritonavir alone or saquinavir plus ritonavir (PIs) may result in increased serum levels of digoxin. 8 Consequently, digoxin levels should be monitored carefully, and the digoxin dose should be adjusted accordingly to reduce the potential for toxic effects. For similar reasons, the international normalized ratio should be carefully monitored when warfarin is administered with antiretrovirals such as atazanavir plus ritonavir or darunavir plus ritonavir 8 (all PIs). Further, PIs slow metabolism of benzodiazepines, increasing the levels of the latter. 8 Unlike digoxin, which can be given while monitoring serum levels, the benzodiazepines midazolam and triazolam should not be administered with most PIs and NNRTIs because of expected interactions leading to dangerous levels of sedation and risk for respiratory depression. 7 In contrast, ART drugs can interact with other drugs, causing subtherapeutic levels of the antiretrovirals or other pharmacological agents. For example, proton pump inhibitors decrease the therapeutic levels of atazanavir (a PI). If a patient is on a nonboosted atazanavir regimen, proton pump inhibitors are not recommended. However, for a patient who is on a boosted atazanavir regimen, the proton pump inhibitor should be administered at least 12 hours before the atazanavir to maintain therapeutic levels. Similarly, rifampin markedly decreases serum PI levels; therefore, coadministration of rifampin and PIs is contraindicated. 8 If drug-drug interactions result in subtherapeutic levels of an antiretroviral, the risk for HIV resistance increases and limits future treatment choices.
As the previous scenario illustrates, critical care nurses must be aware of drug-drug interactions and should consult other members of the health care team, especially the infectious disease specialist and the clinical pharmacologist, to obtain guidance and drug-administering parameters. In the scenario, the proton pump inhibitor could be replaced by another agent, such as an H 2 Continuing or Stopping ART in the ICU No clear evidence indicates whether an established ART regimen should be continued or stopped when a known HIV-infected patient is admitted to the ICU. 2, 3 As previously noted, the risk for drug-drug interactions is marked. However, other issues may also present administration challenges. Consider another scenario:
A 43-year-old man is admitted to the ICU because of a subarachnoid hemorrhage. After HIV infection was diagnosed 7 years before, he started on ART, and he has been adherent to his prescribed regimen ever since. His viral load has been undetectable for more than 6 years, and his most recent CD4 + T-cell count was 710 cells/μL. The ICU health care team must determine whether to stop or continue his ART as he receives treatment for the subarachnoid hemorrhage.
In this situation, the health care team may continue to administer ART as scheduled. In patients with chronic HIV infection, effective ART helps improve immune function and decreases the risks for opportunistic infections and cancers. 8 Additionally, ART could have a role in decreasing complications and mortality in critically ill patients with HIV infection. 3, 7, 8, 13 However, when ART is administered in the ICU, several important factors must be considered. In addition to potential drug-drug interactions, other relevant concerns include the potential dietary restrictions (nothing by mouth), 3, 14 gastrointestinal absorption problems related to decreased motility, altered gastric pH as part of a gastrointestinal prophylaxis regimen, 8 and lack of ART availability beyond oral formulations. 3 Because many ART medications are available only in pill, tablet, or capsule formulations, administration of the medications via nasogastric tubes is difficult. Further, antiretrovirals such as ritonavir and raltegravir, 2 medications used in first-line regimens, should not be crushed. 4 Additionally, some antiretrovirals must be taken on an empty stomach (eg, efavirenz/emtricitabine/tenofovir), whereas others must be taken with food (eg, atazanavir). Failure to adhere to the medication administration guidelines can inhibit absorption and result in suboptimal blood levels.
14 Table 2 provides information about administration of antiretroviral agents.
In addition to potential interactions, unsuitable drug formulations, or difficulties with administering ART appropriately with or without food, nurses must consider differences in absorption of antiretroviral agents because of variations in gastric acid concentrations or physiological stress. Because of the risk for gastric ulcers, many ICU patients are prescribed medications to reduce the amount of gastric acid. Some antiretroviral medications, such as amprenavir, delavirdine, and zalcitabine, are absorbed better in acidic environments, and medications that decrease stomach acid inhibit absorption of these agents. 4 The widespread physiological stress experienced by critically ill patients may also cause abnormal gastrointestinal function, leading to poor absorption. 3, 4 In many instances, the health care team will need to evaluate ART administration throughout a patient's hospitalization and consider the potential complications associated with stopping ART or with impaired drug absorption. In other instances, the health care team may choose to stop all antiretroviral drugs until the patient is discharged from the ICU if a risk for drug-drug interactions or a lack of suitability for enteral delivery exists. When a patient's condition is stabilized and the health care team determines a pharmacological risk no longer exists, ART can be resumed.
Stopping antiretroviral drugs in the ICU may lead to decreases in CD4 + T-cell counts, resulting in immunosuppression. 8 Without ART, viral replication is not suppressed, and the risk that the viral load will rebound is high. However, evidence on how long to stop ART, specifically in the ICU, is inconclusive. Additional research must be conducted to determine the length of time an ICU patient can safely abstain from ART before the patient begins to experience dangerous immunosuppression and the risk for HIV-associated complications.
Evidence suggests that stopping individual drugs in an ART regimen while administering others can lead to viral mutation and resistance, which may render the regimen ineffective when fully resumed. 15 Withdrawing antiretroviral drugs while concurrently administering ICU drugs may result in functional monotherapy, a drug with a longer half-life will continue to be active after the other drugs have been metabolized, and the patient will have only a single active drug in his or her system. 8, 15 Functional monotherapy may lead to drug resistance in the virus, eliminating possible treatment options for an HIV-positive patient, and does not meet the contemporary standard of care. 8, 15 Generally, persons with HIV/AIDS should either take all medications in the prescribed regimen or not take any antiretroviral to prevent resistance and future challenges in treatment. These important factors, including potential interactions, unsuitable formulations, issues related to drug absorption, potential immunosuppression, and functional monotherapy, present a dilemma in the delicate balance between caring for the underlying condition of HIV/AIDS and treating the primary reason the patient is admitted to the ICU. Ultimately, the decision to stop or continue ART in the ICU should be made by the interdisciplinary health care team after all potential benefits and risks are thoroughly considered.
Starting ART in the ICU
As many as 40% of persons infected with HIV who are admitted to the ICU are unaware of their HIV status and have no history of treatment with antiretroviral drugs. 4, 7 For a treatment-naive ICU patient whose HIV infection is diagnosed through rapid testing, the health care team must decide whether or not to start ART while the patient is in the ICU. Consider the following scenario:
A 37-year-old man with no significant medical history is admitted to the ICU with pneumonia. Assessment findings and chest radiographs are suggestive of Pneumocystis pneumonia. The health care team suspects HIV disease and performs rapid testing for diagnosis of HIV infection. The results indicate the patient is infected with the virus. The health care team must now determine whether to initiate or defer ART.
According to the 2012 guidelines, 8 ART should be considered for all HIV-positive persons. Among HIVpositive persons admitted to the ICU who are treatment naive, several conditions may favor more rapid initiation of ART. These conditions include pregnancy, an AIDSdefining condition, an acute opportunistic infection, CD4 + T-cell counts less than 200 cells/μL, HIV-associated nephropathy, coinfection with HIV and hepatitis B virus, rapidly declining CD4 + T-cell counts (eg, >100 cells/μL decrease per year), and/or higher viral loads (eg, >100000 copies/mL). 8 Current treatment guidelines and some research suggest that patients who receive ART during their ICU stay have a lower mortality rate than do those who do not. 16, 17 Inasmuch as ART improves immune function in HIVinfected patients, and because of their poor prognosis, severely immunocompromised patients most likely will receive the greatest benefit from starting ART in the ICU. 7 However, even if the initiation of ART is thought to be beneficial for HIV-infected patients in the ICU, the health care team must consider many factors before starting therapy. These factors include results from tests to determine if the HIV is drug resistant, antiretroviral pharmacokinetics, antiretroviral-drug interactions, potential toxic effects, and anticipated surgery resulting in an extended interruption of ART after the therapy is started. 7, 8 Additionally, deciding to defer initiation of ART should include consideration of a poor prognosis associated with a concomitant medical condition for which ART would not enhance survival or yield qualityof-life benefits; examples include patients who have incurable non-HIV-related malignant neoplasms or who have end-stage liver disease but are not being considered for liver transplantation. IRIS is characterized by a disease-specific or pathogen-specific inflammatory response that is triggered by initiation, reinitiation, or change to a more effective ART regimen. Currently, the pathogenesis of IRIS is not well-known, and its development depends on the cause of infection. 9 However, for patients with other opportunistic infections, such as Pneumocystis jiroveci pneumonia, early initiation of ART is associated with increased survival.
In patients who are starting ART, critical care nurses have a vital role in consistent assessment for the development of IRIS, which may result in worsening of an already critical disease. Typically, IRIS may occur within days or months of changes in ART. 4 The syndrome is accompanied by an increase in CD4 + T-cell count and/or a rapid decrease in viral load. Additionally, patients may have fever and exacerbation of underlying infection. 8 Patients with IRIS can also have severe pulmonary issues leading to respiratory distress. 8 Prednisone (1-2 mg/kg) treatment for 1 to 2 weeks, followed by tapering off of the treatment, is the preferred regimen for managing the signs and symptoms of IRIS. 9 The Figure provides an algorithm for making clinical decisions about initiating ART in the ICU.
Conclusion
Because of the complexities associated with ART in the ICU, critical care nurses must consider the risks for drug-drug interactions and acknowledge the challenges associated with administration and initiation of ART. To facilitate evidence-based, quality care, critical care nurses must collaborate with other members of the multidisciplinary health care team, including infectious disease specialists and clinical pharmacists, to address these complex issues. Through collaboration, the risk for resistance can be reduced, patient safety protected, and quality care delivered. CCN 
CCN Fast Facts
Facts
• Because of antiretroviral therapy, persons who have human immunodeficiency virus (HIV) infection or have progressed to AIDS are living longer. As a result, the likelihood that they will need critical care nursing is increasing.
• Unlike in years past, when these patients were often admitted because of the consequences of immunosuppression, today they are also being cared for in critical care units for other conditions associated with aging, other chronic health conditions, and trauma.
• When persons who have HIV disease or AIDS are admitted to the intensive care unit, nurses must be prepared to provide care, especially management of complexities associated with antiretroviral therapy.
ART and Drug Interactions
• Critical care nurses must be aware of drug-drug interactions and should consult other members of the health care team, especially the infectious disease specialist and the clinical pharmacologist, to obtain guidance and drug-administering parameters.
• Critical care nurses are a patient's last line of defense against preventable complications, and the nurses should ensure that potential interactions are addressed.
Continuing or Stopping ART in the ICU
• In addition to potential interactions, unsuitable drug formulations, or difficulties with administering ART appropriately with or without food, nurses must consider differences in absorption of antiretroviral agents because of variations in gastric acid concentrations or physiological stress.
• The health care team must evaluate ART administration throughout a patient's hospitalization and consider the potential complications associated with stopping ART or with impaired drug absorption. The health care team may choose to stop all antiretroviral drugs until the patient is discharged from the ICU if a risk for drug-drug interactions or a lack of suitability for enteral delivery exists. When a patient's condition is stabilized, ART can be resumed.
• Stopping individual drugs in an ART regimen while administering others can lead to viral mutation and resistance, which may render the regimen ineffective when fully resumed. Withdrawing antiretroviral drugs while concurrently administering ICU drugs may result in functional monotherapy, a drug with a longer half-life will continue to be active after the other drugs have been metabolized, and the patient will have only a single active drug in his or her system. Functional monotherapy may lead to drug resistance in the virus, eliminating possible treatment options for an HIV-positive patient. Generally, persons with HIV/AIDS should either take all medications in the prescribed regimen or not take any antiretroviral to prevent resistance and future challenges in treatment.
Starting ART in the ICU
• For a treatment-naive ICU patient whose HIV infection is diagnosed through rapid testing, the health care team must decide whether or not to start ART while the patient is in the ICU.
• In patients who are starting ART, critical care nurses have a vital role in consistent assessment for the development of immune reconstitution inflammatory syndrome (IRIS), which may result in worsening of an already critical disease. Typically, IRIS may occur within days or months of changes in ART. Prednisone (1-2 mg/kg) treatment for 1 to 2 weeks, followed by tapering off of the treatment, is the preferred regimen for managing the signs and symptoms of IRIS. CCN
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